MetLife (MET)

NYSE Financials Life & Health Insurance S&P 500
$98.27
-1.48 (-1.48%)
Close of Nov 06, 2026 · end-of-day data
SMA 50SMA 2005Y/10Y use weekly candles (10/40-week averages)

Performance

price return
1W-1.8%
1M-0.2%
3M+1.3%
6M+25.9%
YTD+24.5%
1Y+24.9%
3Y+63.8%
5Y+56.5%

Key statistics

Full financials →
Market cap$61.8B
P/E (TTM)12.8
EPS (TTM, diluted)$7.67
P/S22.17
P/B2.78
EV / EBITDA8.9
Revenue (TTM)$2.79B
Revenue growth+16.5%
Net margin184.0%
ROE23.1%
Debt / equity0.86
FCF yield22.7%
Dividend yield2.39%
Payout ratio31%
Beta (1Y)0.66
Volatility (1Y)24.1%
52-week range$67.33 – $106.72
Avg volume (50D)3.18M

Revenue & net income — last 8 quarters

Statements →

Chart pattern: Rising Wedge (daily)

Forming
MET Rising Wedge chart

Trigger $97.78 (-0.5% away). Details →

Nov 4, 4:22 PM ET

MetLife Reports Third Quarter 2026 Results with Net Income of $2.4 Billion

Positive earnings 2.027.018.01

MetLife reported its third-quarter 2026 financial results, highlighted by net income of $2.4 billion, or $3.67 per share, driven by net derivative gains and higher adjusted earnings. Adjusted earnings increased 12% to $1.8 billion, supported by higher variable investment income, broad-based volume growth, and favorable underwriting. The company returned approximately $1 billion to shareholders through share repurchases and common stock dividends during the quarter.

  • Net income increased 187% to $2.4 billion, or $3.67 per share, for the third quarter of 2026.
  • Adjusted earnings rose 12% to $1.8 billion, or $2.78 per share.
  • Premiums, fees and other revenues increased 12% to $14.1 billion.
  • Total assets under management for MetLife Investment Management reached $723.4 billion.
Read the filing on SEC.gov ↗
Aug 5, 4:31 PM ET

MetLife Q2 adjusted EPS rises 20% to $2.43; board approves $3.0 billion buyback

Positive earnings Written later 2.027.018.01

MetLife reported results for the quarter ended June 30, 2026, with adjusted earnings up 15% to $1.6 billion and adjusted earnings per share up 20% to $2.43. Net income rose 1% to $705 million, or $1.09 per share, and premiums, fees and other revenues grew 7% to $13.7 billion. The board also approved a new $3.0 billion authorization to repurchase common stock.

  • Adjusted earnings rose 15% to $1.6 billion ($1,573 million); adjusted earnings per share rose 20% to $2.43.
  • Net income rose 1% to $705 million, or $1.09 per share, up 6% on a per-share basis.
  • Premiums, fees and other revenues rose 7% to $13.7 billion; net investment income rose 18% to $6.7 billion.
  • On August 5, 2026, the board approved a new $3.0 billion common stock repurchase authorization.
Read the filing on SEC.gov ↗
May 6, 4:31 PM ET

MetLife Q1 2026 adjusted EPS rises 23% to $2.42; net income up 30% to $1.1 billion

Positive earnings Written later 2.027.018.01

MetLife reported first-quarter 2026 results that improved on the prior-year quarter, with net income up 30% to $1.1 billion and adjusted earnings up 18% to $1.6 billion. Adjusted premiums, fees and other revenues excluding pension risk transfers rose 10% to $13.3 billion, and the company returned over $1.1 billion to shareholders through buybacks and dividends.

  • Net income was $1.1 billion, or $1.74 per share, up 30% (36% per share); adjusted earnings per share rose 23% to $2.42.
  • Premiums, fees and other revenues rose 5% to $14.3 billion; excluding pension risk transfers, they rose 10% to $13.3 billion.
  • Variable investment income rose 58% to $518 million, driven by higher private equity returns.
  • Holding company cash and liquid assets totaled $3.9 billion at March 31, 2026, at the top of the target range.
Read the filing on SEC.gov ↗
Feb 24, 4:21 PM ET

MetLife adds two independent directors, Daniel Glaser and Michelle Seitz, expanding board to 13

Neutral leadership Written later 5.02

MetLife's Board increased its size from eleven to thirteen directors and elected Daniel S. Glaser and Michelle R. Seitz, both determined to be independent. The new directors receive the standard non-management director pay, which is a $355,000 annual retainer split between shares and cash.

  • Board expanded from eleven to thirteen directors on February 24, 2026, effective immediately
  • Glaser joins the Audit, Compensation, and Finance and Risk committees; Seitz joins the Compensation, Governance and Corporate Responsibility, and Investment committees
  • Standard non-management retainer is $355,000 per year: $205,000 in company stock and $150,000 in cash, with partial-year service pro-rated
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Recent SEC filings

EDGAR ↗

Famous investors who own MET

All investors →
InvestorValue% of portfolioLast quarter
Ray Dalio Bridgewater Associates $52.59M0.22% Reduced

From each investor's latest 13F filing (Q2 2026); positions are as of the quarter end and filed up to 45 days later.

Trades disclosed by members of Congress

All MET congressional trades →
TradedMemberTypeAmount
Aug 06, 2025Gilbert Cisneros CA-31Sell (partial)$1,001 – $15,000
Jul 11, 2025Ritchie John Torres NY-15Sell$1,001 – $15,000

From House periodic transaction reports (STOCK Act); amounts are the form's ranges.

Insider transactions

All insider trades →
DateInsiderTypeSharesPriceValue
Oct 01Johnson Jeh C.
Director
Award544$94.35$51.33K
Oct 01Hubbard Robert Glenn
Director
Award941$94.35$88.78K
Oct 01Mumenthaler Christian Stephane
Director
Award544$94.35$51.33K
Oct 01Harris Carla A
Director
Award544$94.35$51.33K
Oct 01Weinberger Mark A
Director
Award544—$0
Oct 01Mckenzie Diana
Director
Award544$94.35$51.33K
Oct 01Seitz Michelle
Director
Award544—$0
Oct 01Hay Laura J
Director
Award544$94.35$51.33K
Oct 01Glaser Daniel S
Director
Award544$94.35$51.33K
Oct 01Kennard William E
Director
Award544$94.35$51.33K

Prices are end-of-day and split-adjusted. Financial data from MetLife's SEC XBRL filings. Not investment advice.